TherapeuticsMD: Income from continuing operations was $164,000 in the second quarter
Key Facts
TherapeuticsMD reported net income from continuing operations of $164,000 in the second quarter of 2026, compared with $545,000 in the same period of 2025, according to a company filing with the U.S. Securities and Exchange Commission. Income from continuing operations declined alongside lower licensing revenue, which the company said is primarily tied to royalties on licensed products. The company said licensing revenue was $869,000 in the second quarter, versus $952,000 a year earlier. It attributed the decline to changes in sales of licensed products. These figures provide a picture of second-quarter performance, while the third-quarter results cited in a TherapeuticsMD news report dated November 13, 2026, could not be verified.
Operating expenses totaled $1.7 million in the second quarter of 2026, an increase of $38,000, or 2.3%, compared with $1.6 million in the second quarter of 2025. The company linked the increase primarily to higher general and administrative expenses and patent write-offs. Total operating expenses exceeded licensing revenue recorded in the quarter, but comparing the two items alone does not represent the company’s full results. In the third quarter of 2025, the company reported net income from continuing operations of $50,000, after a net loss of $567,000 in the third quarter of 2024. Basic and diluted earnings per share in the third quarter of 2024 were a loss of $0.05, while they were $0.00 in the third quarter of 2025.
Licensing revenue was $784,000 in the third quarter of 2025, up $237,000 from $547,000 in the same period of 2024. The company said licensing revenue in the first and second quarters of 2026 came entirely from Mayne Pharma, Theramex and Knight. The company described royalties on products licensed to pharmaceutical companies with commercial capabilities in their territories as its primary revenue source following the Mayne Pharma transaction. This model means revenue depends on product sales by licensees, according to the company’s explanation in its filing. On June 30, 2026, cash and cash equivalents totaled $9.2 million.
TherapeuticsMD said it changed its business in December 2022 to become a pharmaceutical royalty company, collecting royalties primarily from licensees. It added that it does not conduct research and development or commercial operations. In its second-quarter results statement, it said it continues to evaluate strategic alternatives that may include an acquisition, merger, asset sale or other strategic transactions. The company did not set a timeline for completing the review. It also said in its filing that it may need to raise additional capital to provide the liquidity needed to fund its operations, and that options may include equity or debt financing.
TXMD shares closed at $1.82 on November 12, 2026, according to EL7 data. The data provided did not include the session’s high and low prices. This reading refers to the closing price on that day and does not provide a comparison with a previous session or an explanation for the share price movement. The net income and earnings-per-share figures attributed to the third quarter of 2026 could not be verified from a reliable, accessible page. Accordingly, the quarterly figures attributable here are the second-quarter results and historical data reported in company filings.